Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue.
Kaliman
J
J
Department of Cardiology, University of Vienna, Austria.
Fitscha
P
P
Barth
H
H
Sinzinger
H
H
D000368:Aged; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D011464:Epoprostenol / Q000627:therapeutic use* / Q000031:analogs & derivatives; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000503:physiopathology; D011465:Prostaglandins, Synthetic / Q000627:therapeutic use*; D011897:Random Allocation; D014652:Vascular Diseases / Q000188:drug therapy* / Q000503:physiopathology
D011465:Prostaglandins, Synthetic; C039188:taprostene; D011464:Epoprostenol